WSFS
ADAP

Wilmington Savings Fund Society’s Adaptimmune Therapeutics ADAP Stock Holding History

Wilmington Savings Fund Society’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-604
Closed -$79 – 1375
2025
Q3 		$79 Hold
604
– – ﹤0.01% 1369
2025
Q2 		$145 Hold
604
– – ﹤0.01% 2025
2025
Q1 		$119 Hold
604
– – ﹤0.01% 2050
2024
Q4 		$325 Hold
604
– – ﹤0.01% 2053
2024
Q3 		$574 Buy
+604
New +$685 ﹤0.01% 2010

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wilmington Savings Fund Society's ADAP Position: Q4 2025 in Review

Wilmington Savings Fund Society sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 604 shares — an estimated $79 sold.

Wilmington Savings Fund Society first reported a position in ADAP in Q3 2024 and held it in 5 quarters. The position peaked at $574 in Q3 2024. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • Wilmington Savings Fund Society reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wilmington Savings Fund Society sold 604 Adaptimmune Therapeutics shares in Q4 2025, an estimated $79.
  • Wilmington Savings Fund Society first reported a position in Adaptimmune Therapeutics in Q3 2024 and held it in 5 quarters.
  • Wilmington Savings Fund Society's Adaptimmune Therapeutics position peaked at $574 in Q3 2024.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Wilmington Savings Fund Society's 13F filing for Q4 2025, filed 12 Feb 2026.